Last updated: 2026-10-16 08:31:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
TransMedics Group, Inc. (TMDX) operates in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $76.98, with a market capitalization of $2.62B and a P/E ratio of 17.49. Over the past 52 weeks, its price has ranged from $60.11 to $156.00. This page covers its latest market performance, valuation, price trends and company information.
$2.62B | |
$76.06 | |
$177.37 | |
$10.00 | |
$76.52 | |
111.00 | |
831.64K | |
17.49 | |
$156.00 | |
$60.11 | |
-- | |
-- |
TransMedics Group, Inc. (TMDX) is trading at $76.98 in pre-market trading as of 2026-10-16 08:19:00, up 0.60% ($0.46) from the previous close of $76.52
Pre-market trading shows how investors are pricing TMDX before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, TransMedics Group, Inc. (TMDX) moved from $81.07 to $76.98, representing a decline of 5.05% ($4.09).
The stock traded between $74.41 and $83.90 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 884.09 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 17.6%
TMDX is currently trading at $76.98, placing it 17.6% of the way from its 52-week low of $60.11 to its 52-week high of $156.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
| Industry | ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS |
| Employees | 898 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of TransMedics Group, Inc. (TMDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.